At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 64 enrolled
Drug / intervention
Sulforaphane Nutraceutical +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind Placebo-Controlled Trial of a Sulforaphane Nutraceutical to Reduce the Symptoms of Schizophrenia
In Brief
A Phase 2 clinical trial evaluating Sulforaphane Nutraceutical and Identical-appearing Placebo for Schizophrenia and Schizoaffective Disorder. Completed, enrolled 64 participants across 1 site.
Detailed Summary
The purpose of this study is to determine if taking a sulforaphane nutraceutical versus a placebo will reduce symptoms of schizophrenia when used in addition to standard antipsychotic medications.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Schizoaffective Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJun 2016
Enrollment StartFeb 2017
Primary CompletionNov 2019
TodayJul 2026
First PostedJun 23, 2016
Enrollment StartFeb 22, 2017
Primary CompletionNov 11, 2019
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 10.0 years ago
Interventions
Sulforaphane Nutraceuticaldrug
Sulforaphane Nutraceutical 6 tablets by mouth daily
Identical-appearing Placebodrug
Identical-appearing Placebo 6 tablets by mouth daily